Based on their promising preclinical activities, Bcl-2/Bcl-xL inhibitor ABT-737 [48] and its oral derivate navitoclax/ABT-263 [49], as well as the highly selective Bcl-2 inhibitor ABT-199 [41], are currently validated in advanced clinical trials in solid tumors, acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), and non-Hodgkin lymphoma (NHL) (https://clinicaltrials.gov). Here, BCL2L1 is linked to non-Hodgkin lymphoma.